Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000167435 | SCV000218291 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-04-26 | criteria provided, single submitter | clinical testing | The p.K686* pathogenic mutation (also known as c.2056A>T), located in coding exon 13 of the NBN gene, results from an A to T substitution at nucleotide position 2056. This changes the amino acid from a lysine to a stop codon within coding exon 13. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV002516520 | SCV003201681 | pathogenic | Microcephaly, normal intelligence and immunodeficiency | 2022-05-10 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 187686). This variant has not been reported in the literature in individuals affected with NBN-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Lys686*) in the NBN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NBN are known to be pathogenic (PMID: 9590180, 16415040). |